NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 165 filers reported holding NEKTAR THERAPEUTICS in Q4 2014. The put-call ratio across all filers is 0.54 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $28,601 | -65.7% | 44,970 | +22.0% | 0.00% | – |
| Q4 2022 | $83,274 | +54.2% | 36,847 | +120.0% | 0.00% | – |
| Q3 2022 | $54,000 | -99.4% | 16,750 | -81.2% | 0.00% | -100.0% |
| Q1 2018 | $9,462,000 | +64.2% | 89,050 | -83.1% | 0.01% | +42.9% |
| Q3 2015 | $5,764,000 | +0.3% | 525,938 | +14.5% | 0.01% | +16.7% |
| Q2 2015 | $5,745,000 | +13.3% | 459,193 | +40.4% | 0.01% | 0.0% |
| Q4 2014 | $5,070,000 | +31.8% | 327,120 | +2.6% | 0.01% | +50.0% |
| Q3 2014 | $3,848,000 | -2.7% | 318,773 | +3.4% | 0.00% | -20.0% |
| Q2 2014 | $3,953,000 | +197.0% | 308,362 | +180.7% | 0.01% | +150.0% |
| Q1 2014 | $1,331,000 | +38.4% | 109,841 | +29.6% | 0.00% | +100.0% |
| Q4 2013 | $962,000 | +15.6% | 84,730 | +6.5% | 0.00% | 0.0% |
| Q3 2013 | $832,000 | -3.4% | 79,590 | +6.8% | 0.00% | 0.0% |
| Q2 2013 | $861,000 | – | 74,530 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 2,000,000 | $67,200,000 | 3.35% |
| First Light Asset Management, LLC | 763,403 | $25,650,000 | 3.33% |
| BRIDGER MANAGEMENT, LLC | 1,238,489 | $41,613,000 | 3.29% |
| Rhenman & Partners Asset Management AB | 734,445 | $24,677,000 | 2.89% |
| BB BIOTECH AG | 2,020,676 | $67,895,000 | 1.71% |
| Gs Investments, Inc. | 54,200 | $1,821,120,000 | 1.43% |
| Artal Group S.A. | 900,000 | $30,240,000 | 1.24% |
| Cormorant Asset Management, LP | 500,000 | $16,800,000 | 1.14% |
| TOBAM | 640,547 | $21,522,000 | 1.09% |
| Bellevue Group AG | 430,026 | $14,449,000 | 0.80% |